← All studies
Journal of Clinical Endocrinology & Metabolism 96: 2430–2439 · 2011Symptoms & thresholds

Reference ranges for testosterone in men generated using LC–MS/MS in healthy non-obese young men (Framingham Heart Study)

This is a widely cited reference-range study. Bhasin et al. measured total testosterone by liquid chromatography–tandem mass spectrometry in healthy, non-obese men aged 19–40 in the Framingham Heart Study, then tested the resulting cut-off in three other cohorts.

Bhasin S., Pencina M., Jasuja G. K. et al.Open the publication DOI: 10.1210/jc.2010-3012

Focus

Reference ranges

Published finding

456

Source

10.1210/jc.2010-3012

Record

Ref 15

Structured abstract

Method

This is a widely cited reference-range study. Bhasin et al. measured total testosterone by liquid chromatography–tandem mass spectrometry in healthy, non-obese men aged 19–40 in the Framingham Heart Study, then tested the resulting cut-off in three other cohorts.

Result

In 456 healthy young men, mean total testosterone was 723.8 ng/dL and the median 698.7 ng/dL. The 2.5th percentile — the lower limit used clinically — was 348.3 ng/dL; for free testosterone 70 pg/mL. Men below these limits more often had slow walking speed, difficulty climbing stairs, frailty and diabetes. In the European Male Ageing Study, men below the limits more often reported sexual symptoms.

What to take with you

Healthy non-obese men 19–40: mean 723.8 ng/dL. The 2.5th percentile — the lower limit labs use — was 348.3 ng/dL. It describes a reference population, not a treatment target.

Why it matters

Healthy non-obese men 19–40: mean 723.8 ng/dL. The 2.5th percentile — the lower limit labs use — was 348.3. A lower limit is a percentile, not a treatment target.

Study frame

Reference ranges

This is a widely cited reference-range study. Bhasin et al. measured total testosterone by liquid chromatography–tandem mass spectrometry in healthy, non-obese men aged 19–40 in the Framingham Heart Study, then tested the resulting cut-off in three other cohorts.

Finding

In 456 healthy young men, mean total testosterone was 723.8 ng/dL and the median 698.7 ng/dL.

Contrast

The 2.5th percentile — the lower limit used clinically — was 348.3 ng/dL; for free testosterone 70 pg/mL.

Context

Men below these limits more often had slow walking speed, difficulty climbing stairs, frailty and diabetes.

DOI

10.1210/jc.2010-3012

Category

Reference ranges

Findings listed

4

Type

As published

What to take from the numbers

Boxes below use only wording already in the published summary for this study.

Reported finding

456

In 456 healthy young men, mean total testosterone was 723.8 ng/dL and the median 698.7 ng/dL.

Reported finding

2.5

The 2.5th percentile — the lower limit used clinically — was 348.3 ng/dL; for free testosterone 70 pg/mL.

Reported finding

3

Men below these limits more often had slow walking speed, difficulty climbing stairs, frailty and diabetes.

A reference range is a statistical description of a contemporary population, not a threshold for who benefits from treatment; the authors themselves ask for prospective validation.

Why it matters when reading your own result

Pulled from the study's own findings.

In 456 healthy young men, mean total testosterone was 723.8 ng/dL and the median 698.7 ng/dL.

Reference ranges

The 2.5th percentile — the lower limit used clinically — was 348.3 ng/dL; for free testosterone 70 pg/mL.

Reference ranges

Men below these limits more often had slow walking speed, difficulty climbing stairs, frailty and diabetes.

Reference ranges

Clinical reading

How to use this page

This is a widely cited reference-range study. Bhasin et al. measured total testosterone by liquid chromatography–tandem mass spectrometry in healthy, non-obese men aged 19–40 in the Framingham Heart Study, then tested the resulting cut-off in three other cohorts.

Your own numbers

Measure before you decide what this page means for you.

The figures here describe men who were actually measured.

  • Total testosterone and SHBG
  • Symptoms written down
  • Haematocrit as a safety baseline
  • Repeat labs before any protocol change